Health committee  —and in order for them to be ready, Mr. Chair, we—

Health committee  Okay. As I was mentioning in response to your previous question, we have a discussion going on with the provinces around how we will do the rollout. In order to have that discussion, we have to have discussions about the number of doses that would be available, and that's the fi

Health committee  —the allocations, Mr. Chair, have not yet been completed, and those discussions are ongoing at this time.

Health committee  I think until the allocations settle out it's hard to know whether their estimation is correct or not.

Health committee  The minister mentioned in her remarks that we have had a number of instances where we do provide material out to the provinces. You'll remember testing and personal protective equipment, as examples. In those instances, usually it was a mix of per capita and some other considerat

Health committee  Which other criteria? Do you mean the other considerations in addition to per capita?

Health committee  That's part of the current discussion that is under way.

Health committee  I don't know that I can speak to when this would be brought to this committee.

Health committee  We're having those discussions with the provinces now and they're progressing very well. It's a very constructive discussion, so we're hopeful in the near term.

Health committee  So far, Canadian domestic manufacturing capacity has been focused on Canadian vaccine development, for instance by companies like VBI, as opposed to international companies.

Health committee  Our relationship with them is to procure their vaccines, and have them manufacture and deliver them to us. They have not asked us to manufacture vaccines for them.

Health committee  Under our existing agreements, we expect to be receiving six million doses by March 31.